Addex Therapeutics Ltd (ADXN)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and...

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Convenes Annual General Meeting 2026

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and...

Form NT 20-F - Notification of inability to timely file Form 20-F

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]